LYMErix Product Liability Suit Seeks Testing For OspA Sensitivity
Executive Summary
A product liability lawsuit is arguing that SmithKline Beecham's LYMErix vaccine should be used only in patients that have been tested for sensitivity to the outer surface protein A Lyme disease vaccine.
You may also be interested in...
GSK Lymerix Withdrawn: Production Stopped, Inventory To Be Discarded
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
GSK Lymerix Withdrawn: Production Stopped, Inventory To Be Discarded
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
FDA Lymerix Study To Test Potential Genetic Marker For Adverse Events
GlaxoSmithKline's Lymerix will be the subject of an FDA case-control study investigating a potential genetic marker for adverse reactions to the Lyme disease vaccine.